# OnCo record pdl1-high-nsclc (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/pdl1-high-nsclc/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "pdl1-high-nsclc" ;
  schema:name "PD-L1-high non-small-cell lung cancer without a driver mutation"@en ;
  schema:alternateName "PD-L1 50 percent or more NSCLC"@en, "PD-L1-high lung cancer"@en, "Driver-negative PD-L1-high non-small-cell lung cancer"@en, "Immunotherapy-eligible lung cancer"@en ;
  schema:description "Lung cancers that carry a lot of PD-L1 and no targetable mutation can be treated with an immunotherapy antibody alone instead of chemotherapy. Pembrolizumab keeps about a third of patients alive at five years, roughly double what chemotherapy achieved, and adding chemotherapy is reserved for those who need a fast response."@en ;
  schema:url <https://onco.cc/cancers/pdl1-high-nsclc/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/PD-L1> ;
  schema:citation <https://en.wikipedia.org/wiki/PD-L1>, <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1450> ;
  onco:tag "subtype-page", "lung" ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/bispecific-antibody/>, <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/companion-diagnostic/> ;
  onco:targets <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/pdl1/>, <https://onco.cc/targets/ctla4/>, <https://onco.cc/targets/vegf/>, <https://onco.cc/targets/trop2/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/cemiplimab/>, <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/drugs/ivonescimab/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/pemetrexed/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/docetaxel/>, <https://onco.cc/drugs/ramucirumab/>, <https://onco.cc/drugs/ventana-pd-l1-sp142/> ;
  onco:companies <https://onco.cc/companies/merck/>, <https://onco.cc/companies/regeneron/>, <https://onco.cc/companies/sanofi/>, <https://onco.cc/companies/roche-genentech/>, <https://onco.cc/companies/bms/>, <https://onco.cc/companies/akeso/>, <https://onco.cc/companies/summit-therapeutics/> ;
  onco:pathways <https://onco.cc/pathways/pd1-checkpoint/>, <https://onco.cc/pathways/nsclc-signalling/> ;
  onco:terms <https://onco.cc/terms/tps/>, <https://onco.cc/terms/pd-l1-testing/>, <https://onco.cc/terms/immuno-oncology/>, <https://onco.cc/terms/immune-checkpoint/>, <https://onco.cc/terms/maintenance-therapy/> ;
  onco:trials <https://onco.cc/trials/keynote-024-189/>, <https://onco.cc/trials/keynote-042/>, <https://onco.cc/trials/empower-lung-1/>, <https://onco.cc/trials/harmoni-2/>, <https://onco.cc/trials/harmoni-3/>, <https://onco.cc/trials/nct05215340/>, <https://onco.cc/trials/tropion-lung01/>, <https://onco.cc/trials/nct05502237/>, <https://onco.cc/trials/lung-map-s1800a/> ;
  onco:people <https://onco.cc/people/martin-reck/>, <https://onco.cc/people/roy-herbst/>, <https://onco.cc/people/tony-mok/>, <https://onco.cc/people/julie-brahmer/>, <https://onco.cc/people/solange-peters/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-keynote-024-nejm-2016/>, <https://onco.cc/key-papers/paper-keynote-189-nejm-2018/>, <https://onco.cc/key-papers/paper-keynote-001-pembrolizumab-nsclc-nejm-2015/>, <https://onco.cc/key-papers/paper-harmoni-2-lancet-2025/> ;
  onco:pipeline <https://onco.cc/trials/harmoni-3/>, <https://onco.cc/drugs/ivonescimab/>, <https://onco.cc/trials/nct05215340/>, <https://onco.cc/trials/tropion-lung01/>, <https://onco.cc/drugs/datopotamab-deruxtecan/>, <https://onco.cc/trials/nct05502237/>, <https://onco.cc/drugs/sacituzumab-tirumotecan/>, <https://onco.cc/ideas/idea-bio2-ctdna-six-week-io-switch/> ;
  onco:standardOfCare <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/trials/keynote-024-189/>, <https://onco.cc/trials/keynote-042/>, <https://onco.cc/drugs/cemiplimab/>, <https://onco.cc/trials/empower-lung-1/>, <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/terms/tps/>, <https://onco.cc/terms/pd-l1-testing/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/trials/keynote-024-189/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/pemetrexed/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/pairings/pd1-plus-chemo-pdl1-low/>, <https://onco.cc/drugs/docetaxel/>, <https://onco.cc/drugs/ramucirumab/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/pemetrexed/>, <https://onco.cc/trials/tropion-lung01/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/terms/immuno-oncology/> .